Dr. Kim on the Importance of Biomarker Testing for Lung Cancer

Edward S. Kim, MD
Published: Tuesday, Nov 28, 2017



Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of biomarker testing in lung cancer.

According to Kim, it is important to gather a patient’s tissue to make an informed decision on the stage of the patient and the treatment options available.

Fifty-percent of patients with non-small cell lung cancer (NSCLC) will have an EGFR, ALK, ROS1, BRAF, or PD-L1 mutation. This determines whether a patient will receive chemotherapy, explains Kim.
 


Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of biomarker testing in lung cancer.

According to Kim, it is important to gather a patient’s tissue to make an informed decision on the stage of the patient and the treatment options available.

Fifty-percent of patients with non-small cell lung cancer (NSCLC) will have an EGFR, ALK, ROS1, BRAF, or PD-L1 mutation. This determines whether a patient will receive chemotherapy, explains Kim.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x